Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

@article{Jaeger2000InductionOP,
  title={Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.},
  author={E. P. Jaeger and Sacha Gnjatic and Yasuhiro Nagata and Elisabeth Stockert and Dirk Jaeger and Julia Karbach and Antje B. Neumann and Julia Rieckenberg and Y T Chen and Gerd Ritter and Eric R Hoffman and Michael Arand and L J Old and Alexander K. Knuth},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2000},
  volume={97 22},
  pages={12198-203}
}
Cancer-testis antigen NY-ESO-1 is one of the most immunogenic tumor antigens defined to date. Spontaneous humoral and CD8+ T-cell responses to NY-ESO-1 are detected in 40-50% of patients with advanced NY-ESO-1-expressing tumors. A clinical trial was initiated to study the immunological effects of intradermal vaccination with 3 HLA-A2-binding NY-ESO-1 peptides in 12 patients with metastatic NY-ESO-1-expressing cancers. Seven patients were NY-ESO-1 serum antibody negative, and five patients were… CONTINUE READING